A pioneering international clinical trial has revealed that a new type of immunotherapy, designed to target some of the most aggressive and hard-to-treat blood cancers, is producing remarkable remission rates in patients who have exhausted all other medical options. Led by researchers at Washington University School of Medicine in St. Louis, the phase 1/2 trial suggests that this "off-the-shelf" treatment could transform the landscape of care for T-cell malignancies, offering a vital bridge to curative procedures for patients previously deemed terminal.
The study, published May 30 in the journal Blood, focused on a specific and innovative form of CAR-T cell immunotherapy. Unlike traditional CAR-T treatments, which have seen significant success in B-cell cancers, this new therapy—known as WU-CART-007—is engineered to confront the unique challenges of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). For the patients enrolled in this trial, the stakes could not have been higher; most had seen their cancer return after multiple rounds of intensive chemotherapy or failed stem cell transplants.
"For patients with these rare and aggressive cancers, who have no other options, this has the potential to become a transformative advance in the field," said the study’s senior author, John F. DiPersio, MD, PhD. DiPersio, the Virginia E. & Sam J. Golman Professor of Medicine at WashU Medicine, originally developed the foundational technology for the therapy in his laboratory. "The trial demonstrated a high likelihood of response to the therapy and even remission. This CAR-T cell treatment shows promise in becoming a ‘bridge-to-transplant’ therapy for patients who would otherwise not be eligible for stem cell transplantation, which is the only potentially curative treatment for these blood cancers."
Addressing an Unmet Clinical Need
The prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma is historically dismal. In the United States, approximately 1,000 people are diagnosed with these specific cancers annually. While initial treatments can be effective for some, those whose cancer does not respond—or those who suffer a relapse after treatment—face a survival window that averages only six months. Statistics show that fewer than 7% of such patients are still living five years after their diagnosis.
The primary difficulty in treating these cancers lies in the nature of the T-cells themselves. T-cells are a cornerstone of the human immune system, responsible for identifying and destroying pathogens and abnormal cells. When these cells become cancerous, they are notoriously difficult to target without simultaneously destroying the healthy immune system. Furthermore, because standard CAR-T therapies use a patient’s own T-cells as the "chassis" for the drug, the manufacturing process for T-cell cancers is fraught with technical hurdles, including the risk of contaminating the final product with the patient’s own cancerous cells.
The WU-CART-007 trial included 28 participants, ranging from adolescents to adults, all of whom suffered from T-ALL or T-LBL that had either failed to respond to initial treatments or had recurred after multiple lines of standard therapy. The trial was conducted across an international network of sites in Australia, Europe, and the United States, with the St. Louis site based at the Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine.
Clinical Efficacy and the "Bridge to Transplant"
The trial was structured with a dose-escalation phase, a standard clinical protocol designed to identify the maximum tolerated dose that provides the highest efficacy with the most manageable side effects. This phase is critical in determining the safety profile of a new biological agent. In the second phase of the trial, 13 patients received the full recommended dose of 900 million CAR-T cells.
